½ÃÀ庸°í¼­
»óǰÄÚµå
1624483

¼¼°èÀÇ Ç÷¾×°¡½º ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð : Á¦Ç° À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°, ¹üÀ§ ¹× ¿¹Ãø

Global Blood Gas Monitoring Systems Market Size By Product Type (Desktop Type, Portable Type), By End-User (Hospitals, Diagnostic Centers), By Geographic Scope And Forecast

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Verified Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 202 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Ç÷¾×°¡½º ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð ¹× Àü¸Á

Ç÷¾×°¡½º ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 43¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç 2031³â¿¡´Â 68¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024-2031³â ¿¬Æò±Õ 5.88% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ³ëÀÎ Àα¸ Áõ°¡¿Í ¸¸¼ºÁúȯÀÇ ºóµµ Áõ°¡·Î ÀÎÇØ ÀÔ¿øÀÌ Áõ°¡ÇÏ¿© ½ÃÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¼¼°èÀÇ Ç÷¾×°¡½º ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå º¸°í¼­´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Æò°¡¸¦ Á¦°øÇÕ´Ï´Ù. ÁÖ¿ä ºÎ¹®, µ¿Çâ, ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, °æÀï ±¸µµ ½ÃÀå¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ¿äÀÎ µîÀ» Á¾ÇÕÀûÀ¸·Î ºÐ¼®ÇÕ´Ï´Ù.

¼¼°èÀÇ Ç÷¾×°¡½º ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå Á¤ÀÇ

Ç÷¾×°¡½º ¸ð´ÏÅÍ´Â Ç÷·ù³» »ê¼Ò, ÀÌ»êȭź¼Ò, »êÀÇ ¾çÀ» ÃøÁ¤ÇÏ´Â ±â±âÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼ÒµéÀº ÆóÁúȯ, ¼îÅ©, ¾à¹° °ú´Ùº¹¿ë µîÀÇ Áúº´ Áø´Ü¿¡ ±â¿©ÇÕ´Ï´Ù. ¹Ì±¹ ±¹¸³»ý¹°°øÇÐÁ¤º¸¼¾ÅÍ(NCBI)¿¡ µû¸£¸é º´¿ø ÁßȯÀÚ½Ç(ICU)°ú ½ÉÀåºñ·á½Ç(CCU)¿¡´Â Ç÷¾×°¡½º ¸ð´ÏÅ͸µ Àåºñ°¡ ÇʼöÀûÀÔ´Ï´Ù. ȯÀÚÀÇ µ¿¸ÆÇ÷ °¡½º(ABG) °Ë»ç´Â ȯÀÚÀÇ »ê¼ÒÈ­ »óÅÂ¿Í »ê¿°±â ÆòÇüÀ» È®ÀÎÇϰí À¯ÁöÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

ÀÌ Áø´Ü ÅøÀÇ À¯È¿¼ºÀº °á°ú¸¦ ÀûÀýÈ÷ ÇØ¼®ÇÒ ¼ö ÀÖ´ÂÁö¿¡ ´Þ·Á ÀÖ½À´Ï´Ù. »ê-¿°±â ±ÕÇüÀÇ ÀÌ»óÀº ´Ù¾çÇÑ Áúº´ÀÇ ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç, ¶§·Î´Â »ý¸íÀ» À§ÇùÇÏ´Â À§Çè¿ä¼Ò°¡ µÉ Á¤µµ·Î ½É°¢ÇØÁú ¼ö ÀÖ½À´Ï´Ù. ÁßȯÀÚ½Ç Àü¹®ÀÇ¿Í ¸¶Ãë°ú Àǻ縦 Æ÷ÇÔÇÑ ¸ðµç ÀÇ»ç´Â »ê-¿°±â ÆòÇü¿¡ ´ëÇØ Àß ¾Ë°í ÀÖ¾î¾ß Çϸç, HCO3-(pCO2¿Í °ü·ÃÇÏ¿©), Ç¥ÁØ¿°±â°úÀ×(SBE), °­ÀÌ¿ÂÂ÷(SID)´Â »ê-¿°±â »ý¸®ÇÐ(SID)¿¡¼­ °¡Àå ³Î¸® »ç¿ëµÇ´Â ¼¼ °¡Áö Á¢±Ù¹ýÀÔ´Ï´Ù.

½ºÆ©¾îÆ®ÀÇ SID¶ó´Â °³³äÀº ¿ÏÀüÈ÷ ÇØ¸®µÈ À½À̿°ú ¾çÀÌ¿ÂÀÇ Â÷ÀÌÀÇ Àý´ë°ªÀ¸·Î Á¤ÀǵǸç, 20³â ÀÌ»ó ÀüºÎÅÍ Á¸ÀçÇØ ¿Ô½À´Ï´Ù. ȯÀÚÀÇ »ê¼ÒÈ­, ȯ±â, »ê¿°±â »óŸ¦ ¾Ë±â À§Çؼ­´Â µ¿¸ÆÇ÷ °¡½º ¸ð´ÏÅ͸µÀÌ ¹Ù¶÷Á÷ÇÑ ¹æ¹ýÀÔ´Ï´Ù. ºñħ½ÀÀû ¸ð´ÏÅ͸µÀÌ ABG ¸ð´ÏÅ͸µÀ» °ÅÀÇ ´ëüÇßÀ½¿¡µµ ºÒ±¸ÇÏ°í ºñħ½ÀÀû ¸ð´ÏÅ͸µ Á¢±Ù¹ýÀÇ Å¸´ç¼ºÀ» È®ÀÎÇÏ°í º¸Á¤Çϱâ À§ÇØ ABG ¸ð´ÏÅ͸µÀº ¿©ÀüÈ÷ °¡Ä¡°¡ ÀÖ½À´Ï´Ù. ÆÞ½º¿Á½Ã¹ÌÅÍ·Î ÃøÁ¤ÇÑ »ê¼Ò Æ÷È­µµ(SpO2)¿Í ½ÇÇè½Ç »ê¼Ò ÃøÁ¤±â·Î ÃøÁ¤ÇÑ »ê¼Ò Æ÷È­µµ(SaO2)´Â µ¿ÀÏÇÏÁö ¾Ê½À´Ï´Ù.

¸Æ¹Ú »ê¼ÒÆ÷È­µµ ÃøÁ¤±â´Â Çì¸ð±Û·ÎºóÀÇ ±â´ÉÀû Æ÷È­µµ¸¦ ÃøÁ¤ÇÕ´Ï´Ù. ȯ¿ø Çì¸ð±Û·Îºó°ú »ê¼ÒÈ­ Çì¸ð±Û·ÎºóÀÇ ÇÕ¿¡ ´ëÇÑ »ê¼ÒÈ­ Çì¸ð±Û·ÎºóÀÇ ¾çÀ» ¹éºÐÀ²·Î Ç¥½ÃÇÑ °ÍÀ» ±â´ÉÀû Æ÷È­µµ¶ó°í ÇÕ´Ï´Ù. ½ÇÇè½Ç Ä۽ùÌÅÍ´Â ´Ù¾çÇÑ ÆÄÀåÀ» »ç¿ëÇÏ¿© ¼­·Î ´Ù¸¥ ÇüÅÂÀÇ Çì¸ð±Û·Îºó(¸ÞÆ®Çì¸ð±Û·Îºó°ú Ä«¸£º¹½ÃÇì¸ð±Û·Îºó)À» ½Äº°ÇÏ¿© ¼ø¼ö ºÐȹ Æ÷È­µµ, Áï Àüü ȯ¿ø Çì¸ð±Û·ÎºóÀÇ ¹éºÐÀ²¿¡ ´ëÇÑ »ê¼ÒÈ­ Çì¸ð±Û·ÎºóÀÇ ¾çÀ» Á¤·®È­ÇÕ´Ï´Ù.

¼¼°èÀÇ Ç÷¾×°¡½º ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå °³¿ä

ÀÚµ¿È­µÈ ÇöÀå Ç÷¾×°¡½º ºÐ¼®±â¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®±â´Â ºü¸¥ °á°ú¸¦ Á¦°øÇϰí, »ç¿ëÀÌ °£ÆíÇϰí, ÈÞ´ë°¡ °£ÆíÇϸç, ªÀº ½Ã°£ ³»¿¡ °á°ú¸¦ ¾òÀ» ¼ö ÀÖÀ¸¸ç, ÁßȯÀڽǰú ÀÀ±Þ½Ç¿¡¼­ »ê¼ÒÈ­ ¹× ȯ±â °ü¸®¿¡ ÇʼöÀûÀÎ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù. Ç÷¾×°¡½º ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ´Ù¸¥ ¿äÀÎÀ¸·Î´Â ³ëÀÎ Àα¸ Áõ°¡¿Í ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, ±â¼úÀûÀ¸·Î Áøº¸µÈ ¹ÙÀÌ¿À ¼¾¼­ ¹× µ¥ÀÌÅÍ ºÐ¼® ¼ÒÇÁÆ®¿þ¾îÀÇ Ã¤Åà Áõ°¡, ±â¼ú ÅëÇÕÇü º¹ÇÕ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, POC Ç÷¾×°¡½º ºÐ¼®±âÀÇ ¼ÒÇüÈ­ µîÀÌ ÀÖ½À´Ï´Ù.

¶ÇÇÑ Ç÷¾×°¡½º ºÐ¼®±â¿Í ÀüÀڰǰ­±â·Ï ¹× °Ë»ç Á¤º¸ ½Ã½ºÅÛ°úÀÇ ÅëÇÕÀº ½ÃÀå È®´ëÀÇ ±âȸ·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅëÇÕ ±â¼úÀº ¿ì¼öÇÑ È¯ÀÚ ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÏ´Â µ¥¿¡µµ µµ¿òÀÌ µË´Ï´Ù. ÇÏÁö¸¸, ÇöÀå Áø·á ±â±â ¹× Ç÷¾×°¡½º ¸ð´ÏÅÍ´Â °¡°ÝÀÌ ºñ½Î°í, ÀϺΠ±¹°¡¿¡¼­´Â ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀÌ ÀÖÀ¸¸ç, ½ÃÀå È®´ë¿¡ ÇѰ谡 ÀÖ½À´Ï´Ù. ¸Æ¹Ú »ê¼Ò ³óµµ°è´Â ICU¿¡¼­ °£ÇæÀû ¸ð´ÏÅ͸µ¿¡ »ç¿ëÇϰųª ½Ç½Ã°£ ¿¬¼Ó »ê¼Ò Æ÷È­µµ ÃøÁ¤¿¡ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü½Å¸¶Ã볪 ÀΰøÈ£Èí Áß¿¡´Â ¿¬¼Ó ¸ð´ÏÅ͸µÀÌ ¸Å¿ì À¯¿ëÇÕ´Ï´Ù. È£Èí±â´ÉÀÌ °æ°è¿¡ Àִ ȯÀÚ¿¡°Ô ½ºÆ®·¹½º°¡ ¸¹Àº Ä¡·á(BAL, ±â°ü¼¼Ã´, ¿ø½ÉºÐ¸®)¸¦ ½ÃÇàÇÏ´Â °æ¿ì, ¸Æ¹Ú »ê¼ÒÆ÷È­µµ ÃøÁ¤±â¸¦ »ç¿ëÇÏ¿© Æ÷È­µµ º¯È­¸¦ °¨ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ »ê¼Ò º¸ÃæÀÌ ÇÊ¿äÇÑÁö ¿©ºÎ¸¦ Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ Ç÷·ù´Â ¹Úµ¿¼ºÀ̱⠶§¹®¿¡ ¸Æ¹Ú »ê¼Ò ³óµµ°è ¼¾¼­ÀÇ Ãâ·ÂÀ» ÀüÀÚÀûÀ¸·Î ó¸®ÇÏ¿© ¸Æ¹Ú ÆÄÇü°ú ½É¹Ú¼ö¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. °á°úÀûÀ¸·Î ÆÞ½º¿Á½Ã¹ÌÅÍ´Â ¸»ÃÊ ¸Æ¹ÚÀÇ ¼Óµµ¿Í ±ÔÄ¢¼ºÀ» ÃßÀûÇÏ´Â µ¥ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿µ¾ç¼Ò(Æ÷µµ´ç, ´Ü¹éÁú, Áö¹æ) ¹× ¹Ì·®¿µ¾ç¼Ò(ºñŸ¹Î ¹× ¹Ì·® ¿ø¼Ò)°ø±Þ Á¶Àý, ¿¡³ÊÁö ¿ä±¸·®°ú °ø±Þ·® »çÀÌÀÇ ÀûÀý¼º Æò°¡, ¸¶Áö¸·À¸·Î Ç÷´ç Á¶ÀýÀº ICUÀÇ ¿µ¾ç ¹× ´ë»ç Ä¡·áÀÇ ¼¼ °¡Áö ÁÖ¿ä ¸ñÇ¥ÀÔ´Ï´Ù.

´Ü¹éÁú°ú ¿¡³ÊÁö °ø±ÞÀÌ ºÎÁ·Çϰųª Ç÷´ç °ü¸®°¡ Á¦´ë·Î ÀÌ·ç¾îÁöÁö ¾ÊÀ¸¸é ICUÀÇ ÀÓ»ó °á°ú°¡ ³ªºüÁø´Ù´Â ¸¹Àº Áõ°Å°¡ ÀÖÀ¸¹Ç·Î ÀÌ´Â ¸Å¿ì Áß¿äÇÑ ¹®Á¦ÀÔ´Ï´Ù. AlereÀÇ Enterprise Point of Care Blood Analysis ½Ã½ºÅÛÀº ½º¸¶Æ®Ä«µå ±â¼úÀ» äÅÃÇÑ À¯ÀÏÇÑ ¹«¼± º£µå»çÀÌµå °Ë»ç ¿É¼ÇÀÔ´Ï´Ù. ÀÌ ÃÖ÷´Ü ±â¼úÀº ȯÀÚÀÇ °á°ú¸¦ PDA(ÈÞ´ë¿ë Á¤º¸ ´Ü¸»±â)³ª ÀüÀڰǰ­±â·ÏÀ¸·Î Á÷Á¢ Àü¼ÛÇϹǷΠÀÇ»ç´Â ȯÀÚÀÇ Ä§´ë ¿·¿¡ ¸Ó¹°·¯ ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù. ÈÞ´ë¿ë ±â±â´Â »ç¿ë, Ãë±Þ ¹× À¯Áöº¸¼ö°¡ °£ÆíÇϹǷΠ¼ö¿ë·üÀÌ ³ô½À´Ï´Ù. ÀϺΠ½ÅÈï ±¹°¡ ½ÃÀå¿¡¼­´Â ÀÌ·¯ÇÑ ±â±âÀÇ °³¹ß ¹× ÆÇ¸Å¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ Ç÷¾×°¡½º ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå : ¼­·Ð

  • ½ÃÀå °³¿ä
  • Á¶»ç ¹üÀ§
  • ÀüÁ¦Á¶°Ç

Á¦2Àå °³¿ä

Á¦3Àå VERIFIED MARKET RESEARCHÀÇ Á¶»ç ¹æ¹ý

  • µ¥ÀÌÅÍ ¸¶ÀÌ´×
  • ¹ë¸®µ¥À̼Ç
  • 1Â÷ ÀÚ·á
  • µ¥ÀÌÅÍ ¼Ò½º ¸®½ºÆ®

Á¦4Àå ¼¼°èÀÇ Ç÷¾×°¡½º ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå Àü¸Á

  • °³¿ä
  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ±âȸ
  • Porter's Five Forces ¸ðµ¨
  • ¹ë·ùüÀÎ ºÐ¼®

Á¦5Àå ¼¼°èÀÇ Ç÷¾×°¡½º ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå : Á¦Ç° À¯Çü

  • °³¿ä
  • Ź»óÇü
  • ÈÞ´ë¿ë À¯Çü

Á¦6Àå ¼¼°èÀÇ Ç÷¾×°¡½º ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • °³¿ä
  • º´¿ø
  • ½ÉÀå Ä«Å×ÅÍ °Ë»ç½Ç
  • Áø´Ü ¼¾ÅÍ
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ Ç÷¾×°¡½º ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå : Áö¿ªº°

  • °³¿ä
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¼¼°èÀÇ ±âŸ Áö¿ª
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå ¼¼°èÀÇ Ç÷¾×°¡½º ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå : °æÀï ±¸µµ

  • °³¿ä
  • °¢»ç ½ÃÀå ¼øÀ§
  • ÁÖ¿ä ¹ßÀü Àü·«

Á¦9Àå ±â¾÷ °³¿ä

  • Abbott Laboratories
  • Alere, Inc.
  • Instrumentation Laboratory
  • Medicacorp
  • Optimedical
  • Radiometer
  • Roche Diagnostics
  • SenTec AG
  • Siemens Healthcare
  • Sphere Medical

Á¦10Àå ºÎ·Ï

  • °ü·Ã Á¶»ç
KSA 25.02.05

Blood Gas Monitoring Systems Market Size And Forecast

Blood Gas Monitoring Systems Market size was valued at USD 4.32 Billion in 2024 and is projected to reach USD 6.83 Billion by 2031, growing at a CAGR of 5.88% from 2024 to 2031 The primary factor driving the market is the growing elderly population and the rising frequency of chronic diseases, which leads to an increase in hospital admissions. The Global Blood Gas Monitoring Systems Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market

Global Blood Gas Monitoring Systems Market Definition

Blood gas monitors are instruments that measure the amount of oxygen, carbon dioxide, and acidity in the bloodstream. These factors contribute to the diagnosis of diseases such as lung disorders, shock, and drug overdoses, among others. According to the National Center for Biotechnology Information (NCBI), for intensive care units (ICU) and Cardiac Care Unit (CCU) rooms in the hospital, blood gas monitoring equipment is essential. The examination of a patient's arterial blood gas (ABG) is crucial for identifying and maintaining their oxygenation status and acid-base balance.

The effectiveness of this diagnostic tool is contingent on the ability to interpret the results appropriately. Acid-base imbalances can cause complications in a variety of diseases, and the aberration can sometimes be so severe that it becomes a life-threatening risk factor. Any physician, including an intensivist and an anesthesiologist, must have a good understanding of acid-base balance. The HCO3- (in the context of pCO2), standard base excess (SBE), and strong ion difference (SID) are the three most extensively utilized approaches to acid-base physiology (SID).

Stewart's idea of SID, which is defined as the absolute difference between totally dissociated anions and cations, has been around for more than 20 years. For determining a patient's oxygenation, ventilation, and acid-base status, arterial blood gas monitoring is the preferred method. Despite the fact that non-invasive monitoring has mostly supplanted ABG monitoring, it is still valuable for validating and calibrating non-invasive monitoring approaches. The oxygen saturation measured by a pulse oximeter (SpO2) and the SaO2 measured by a laboratory cooximeter is not the same.

The functional saturation of hemoglobin is measured by the pulse oximeter. The amount of oxygenated hemoglobin in a percentage form of total reduced and oxygenated hemoglobin is known as functional saturation. Cooximeters in laboratories uses various wavelengths to discriminate between different forms of hemoglobin (methemoglobin and carboxyhemoglobin) and so quantify genuine fractional saturation, or the amount of oxygenated hemoglobin in a percentage form of the total reduced.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Blood Gas Monitoring Systems Market Overview

The increased demand for automated and point-of-care blood gas analyzer devices is mostly responsible for the market's expansion. These analyzers provide quick results, are simple to use, portable, and have quick turnaround times, making them essential tools for managing oxygenation and ventilation in ICUs and emergency rooms. Other factors driving the growth of the Blood Gas Monitoring Systems Market include an older population and an increase in the prevalence of chronic diseases, increased adoption of technologically advanced biosensors and data analysis software, increasing demand for technology-integrated combined systems, and miniaturization of POC blood gas analyzers.

In addition, the integration of blood gas analyzers with electronic medical records and laboratory information systems is presenting a profitable opportunity for market expansion. These integrated technologies not only allow for excellent patient monitoring but also help to streamline the workflow. However, high prices for point-of-care devices and blood gas monitors, as well as severe regulatory requirements in some countries, limit market expansion. The pulse oximeter can be used in the ICU for intermittent monitoring or to offer a continuous real-time oxygen saturation reading. During general anesthesia or ventilation, continuous monitoring is very beneficial. When stressful treatments are performed on patients with borderline respiratory function (BALs, tracheal washes, centesis), the pulse oximeter can be utilized to detect changes in saturation.

It can help us assess whether or not more oxygen supplementation is required. Furthermore, because blood flow is pulsatile, the pulse oximeter sensor's output can be electronically processed to provide a pulse waveform and heart rate. As a result, the pulse oximeter can be used to track the rate and regularity of peripheral pulses. The regulation of macronutrients (glucose, protein, fat) and micronutrients (vitamins and trace elements) delivery, second, the assessment of the adequacy between energy needs and delivery, and finally, glycaemic control are the three primary goals of nutritional and metabolic care in the ICU.

This is a critical issue since a large body of evidence shows that inadequate protein and energy coverage, as well as poor glycemic management, are both linked to a poor clinical outcome in the ICU. The Alere (San Diego) Enterprise Point of Care blood analysis system is the only wireless bedside testing option that employs Smartcard technology. This cutting-edge technology sends patient results straight to a personal digital assistant (PDA) and the electronic medical record, allowing the doctor to remain at the patient's bedside. The portable devices are simple to use, handle, and maintain, which contributes to their higher acceptance rate. Several businesses are making investments in the development and marketing of these items. Though portable devices have an advantage over traditional devices.

Global Blood Gas Monitoring Systems Market Segmentation Analysis

The Global Blood Gas Monitoring Systems Market is Segmented on the basis of Product Type, End-User, And Geography.

Blood Gas Monitoring Systems Market, By Product Type

  • Desktop Type
  • Portable Type

Based on Product Type, The market is segmented into Desktop Type and Portable Type. There are numerous advantages to using an LED monitor. The biggest advantage is that they offer the highest image quality currently available. In general, a patient monitoring device consists of a sensor for gathering critical patient data (e.g., heart rate) and an interconnect solution (e.g., PCBs, connectors, wire, etc.) for transmitting the data to the capital equipment. The patient monitoring device component of a pulse oximeter, for example, is the piece that clips to your finger and senses and communicates your pulse to the capital equipment.

Blood Gas Monitoring Systems Market, By End-User

  • Hospitals
  • Cardiac Catheterization Laboratory
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Others

Based on End-User, The market is segmented into Hospitals, Cardiac Catheterization Laboratory, Diagnostic Centers, Ambulatory Surgical Centers, Others. A hospital is a medical facility that treats patients with specialized health science and auxiliary healthcare personnel as well as medical equipment. Doctors use catheters instead of surgery to diagnose and treat heart diseases in the cardiac catheterization laboratory. A catheterization lab, rather than an operating room, can safely perform a variety of procedures. Catheters are plastic tubes that resemble spaghetti and are used to introduce special devices to diagnose or treat heart problems.

Blood Gas Monitoring Systems Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, The Global Blood Gas Monitoring Systems Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. he Asia Pacific region is expected to witness a significant CAGR during the forecast period. This is primarily due to the primary factor driving the market is the growing elderly population and the rising frequency of chronic diseases, which leads to an increase in hospital admissions.

Key Players

  • The "Global Blood Gas Monitoring Systems Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as
  • Abbott Laboratories, Alere, Inc, Instrumentation Laboratory, Mediacorp, Optimedical, Radiometer, Roche Diagnostics, SenTec AG, Siemens Healthcare, Sphere Medical.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • November 2020, In India, Abbott launched the FreeStyle Blood Glucose Monitor for diabetic adults and children (over the age of four) as well as women with gestational diabetes (diabetes during pregnancy).
  • November 2021, Abbott released late-breaking data from the global Leadless II IDE study, which looked at Abbott's investigational Aveir leadless pacemaker in people with specific irregular heart rhythms.
  • Jan 2019, Perimed AB and Radiometer Medical ApS have partnered to accelerate and increase the marketing of Perimed's PeriFlux 6000 CPO 2 standalone system.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLOOD GAS MONITORING SYSTEMS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL BLOOD GAS MONITORING SYSTEMS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL BLOOD GAS MONITORING SYSTEMS MARKET, PRODUCT TYPE

  • 5.1 Overview
  • 5.2 Desktop Type
  • 5.3 Portable Type

6 GLOBAL BLOOD GAS MONITORING SYSTEMS MARKET, BY END-USER

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Cardiac Catheterization Laboratory
  • 6.4 Diagnostic Centers
  • 6.5 Ambulatory Surgical Centers
  • 6.6 Others

7 GLOBAL BLOOD GAS MONITORING SYSTEMS MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East and Africa

8 GLOBAL BLOOD GAS MONITORING SYSTEMS MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Abbott Laboratories
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Alere, Inc.
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Instrumentation Laboratory
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Medicacorp
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Optimedical
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Radiometer
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Roche Diagnostics
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 SenTec AG
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Siemens Healthcare
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Sphere Medical
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 Appendix

  • 10.1 Related Research
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦